ADALIMUMAB, ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS-COST EFFECTIVENESS ANALYSIS IN POLISH SETTINGS

被引：0
|
作者：
Macioch, T. [1 ]
Niewada, M. [1 ]
Wrona, W. [1 ]
Golicki, D. [1 ]
Hermanowski, T. [1 ]
机构：
[1] Med Univ Warsaw, Warsaw, Poland
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66790-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A543 / A543
页数：1
相关论文
共 50 条
  • [1] Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
    Wailoo, Allan
    Bansback, Nick
    Chilcott, Jim
    RHEUMATOLOGY, 2008, 47 (02) : 119 - 120
  • [2] Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
    Kobelt, G.
    RHEUMATOLOGY, 2008, 47 (10) : 1589 - 1590
  • [3] Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply
    Wailoo, A.
    Bansback, N.
    Chilcott, J.
    RHEUMATOLOGY, 2008, 47 (10) : 1590 - 1590
  • [4] ADALIMUMAB, ETANERCEPT AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS-BUDGET IMPACT ANALYSIS ON POLISH NATIONAL HEALTH FUND
    Macioch, T.
    Niewada, M.
    Wrona, W.
    Golicki, D.
    Hermanowski, T.
    VALUE IN HEALTH, 2008, 11 (06) : A541 - A541
  • [5] Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: A systematic review and economic evaluation
    McLeod, C.
    Bagust, A.
    Boland, A.
    Dagenais, P.
    Dickson, R.
    Dundar, Y.
    Hill, R. A.
    Jones, A.
    Mota, R. Mujica
    Walley, T.
    HEALTH TECHNOLOGY ASSESSMENT, 2007, 11 (28) : IX - +
  • [6] Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice
    Escudero-Vilaplana, Vicente
    Ramirez-Herraiz, Esther
    Alanon-Plaza, Estefania
    Trovato-Lopez, Nicolas
    Garcia-Vicuna, Rosario
    Carreno-Perez, Luis
    Morell-Baladron, Alberto
    Sanjurjo-Saez, Maria
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (05) : 808 - 814
  • [7] Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice
    Vicente Escudero-Vilaplana
    Esther Ramírez-Herráiz
    Estefanía Alañón-Plaza
    Nicolás Trovato-López
    Rosario García-Vicuña
    Luis Carreño-Pérez
    Alberto Morell-Baladrón
    María Sanjurjo-Sáez
    International Journal of Clinical Pharmacy, 2015, 37 : 808 - 814
  • [8] Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom
    Botteman, M. F.
    Hay, J. W.
    Luo, M. P.
    Curry, A. S.
    Wong, R. L.
    van Hout, B. A.
    RHEUMATOLOGY, 2007, 46 (08) : 1320 - 1328
  • [9] The economic impact of etanercept and infliximab treatment in ankylosing spondylitis
    Duff, SB
    Yeh, Y
    Yu, EB
    Woolley, JM
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 400 - 400
  • [10] The cost-effectiveness of infliximab (Remicade®) in the treatment of ankylosing spondylitis in Canada
    Kobelt, G
    Andlin-Sobocki, P
    Maksymowych, WP
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (04) : 732 - 740
12345